Shares of T2 Biosystems TTOO rose in after-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share were up 68.18% year over year to ($0.07), which were in line with the estimate of ($0.07).
Revenue of $6,956,000 up by 173.32% from the same period last year, which beat the estimate of $6,440,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
T2 Biosystems hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: May 06, 2021
Time: 04:30 PM
ET Webcast URL: http://public.viavid.com/player/index.php?id=144509
Technicals
52-week high: $3.79
Company's 52-week low was at $0.48
Price action over last quarter: down 13.75%
Company Overview
T2 Biosystems Inc provides rapid in vitro diagnostic tests to hospitals and laboratories. Its core technology is T2 Magnetic Resonance (T2MR) technology, which can detect a variety of molecular targets directly from whole blood. T2MR technology enables the T2Dx system, which is fully automated from patient sample to result for its panels focused on bacterial and fungal infections that could cause sepsis, and its pipeline panel for Lyme disease.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
